Biomarkers are measurable biological indicators that reveal what is happening inside an organism, from normal physiology to disease and treatment response. They can be molecules, cells, structures, or functional signals, detected in blood, urine, tissue, or through imaging and physiological measurements.

Research distinguishes several types. Diagnostic biomarkers help identify diseases such as cancers or cardiovascular conditions at earlier, often more treatable stages. Prognostic biomarkers predict how a disease is likely to progress, independent of therapy. Predictive biomarkers forecast how a patient will respond to a specific treatment and are central to personalized medicine, for example guiding targeted cancer therapies. Pharmacodynamic biomarkers track how a body responds to a drug, supporting dose optimization and safety assessments.

Modern biomarker discovery relies heavily on omics technologies, including genomics, transcriptomics, proteomics, and metabolomics. These large scale approaches generate complex datasets that require advanced biostatistics, machine learning, and rigorous validation. Reproducibility and standardization remain key challenges, especially when moving from early discovery to clinical use.

Non invasive and minimally invasive biomarkers are a major focus, such as liquid biopsies that detect tumor derived DNA or cells in the bloodstream. In neurology, imaging and fluid biomarkers aim to diagnose conditions like Alzheimer disease before symptoms become severe. In cardiology, circulating proteins and functional tests refine risk prediction and guide interventions.

Ethical and regulatory considerations shape biomarker implementation, including data privacy, equitable access, and clear evidence of clinical benefit. Overall, biomarkers are transforming biomedical research and clinical decision making by providing more precise, individualized information about health and disease.